Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1

ConclusionThrough  ~5 years, fostemsavir + OBT demonstrated durable virologic and immunologic responses with no new safety concerns between Weeks 96 and 240, supporting this regimen as a key therapeutic option for HTE people with multidrug-resistant HIV-1.Trial registrationClinicalTrials.gov, NCT02362503.
Source: Infectious Diseases and Therapy - Category: Infectious Diseases Source Type: research